Company intelligence / Profile preview

Stuart Therapeutics

Stuart, Florida, United Statesstuarttherapeutics.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

The company’s lead candidate ST‑100 completed a successful Phase II trial in dry eye disease. The study met its primary endpoint with statistically significant improvement in Schirmer’s Test Responder Rate at day 28 and showed improvements in ocular discomfort as early as day 14. Additional programs are at earlier stages targeting other ophthalmic diseases.

Therapeutic areas: Ophthalmology
Modalities: Synthetic proteins (Collagen Mimetic Peptides)Peptides
Industry: Biotech

Drug pipeline

2 assets

vezocolmitide

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships publicly disclosed as of May 2025.

Beyond the preview

Go deeper on Stuart Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stuart Therapeutics.

Explore the full profile